Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model

The Journal of Urology
Mototsugu MuramakiS Kamidono

Abstract

TNP-470 (O-(chloroacetylcarbamoyl)fumagillol) is a potent inhibitor of angiogenesis that was reported to enhance synergistically the antitumor effects of cytotoxic agents. We evaluated the effectiveness of combined treatment with TNP-470 and gemcitabine in vitro and in vivo using highly metastatic human bladder cancer KoTCC-1 cells. The in vitro growth inhibitory and apoptotic effects of gemcitabine and/or TNP-470 on KoTCC-1 cells were assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and TUNEL staining, respectively. We then evaluated the combined effect of gemcitabine and TNP-470 therapy after subcutaneous and orthotopic injection of KoTCC-1 cells into athymic nude mice. Established tumors were analyzed by TUNEL staining and immunohistochemical staining of CD31 to quantify microvessel density. In vitro TNP-470 enhanced the cytotoxic effect of gemcitabine on KoTCC-1 cells, decreasing its IC50 by more than 50%. This combined treatment significantly induced apoptosis compared with treatment with either agent alone. In vivo combined treatment with TNP-470 and gemcitabine significantly decreased tumor growth after subcutaneous and orthotopic injection into athymic nude mice and significant...Continue Reading

References

Nov 1, 1995·Journal of the National Cancer Institute·B H BochnerP W Nichols
Apr 17, 1999·British Journal of Cancer·H MiyakeS Kamidono
Aug 6, 2000·British Journal of Haematology·M MinischettiA F Dammacco
May 29, 2002·Surgical Oncology·Edward H Streeter, Adrian L Harris
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstWaun Ki Hong

❮ Previous
Next ❯

Citations

Dec 25, 2010·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Dongxiao YaoXianli Zhu
Aug 27, 2009·Biologics : Targets & Therapy·Vito Lorusso
Jul 14, 2012·Journal of Toxicology and Environmental Health. Part a·Rosário Pinto-LeitePaula Oliveira
Jun 23, 2009·Expert Opinion on Drug Delivery·M WirthF Gabor
Nov 18, 2008·Expert Opinion on Investigational Drugs·Alexandros LekasAndreas C Lazaris
Aug 29, 2006·Cancer Treatment Reviews·D PectasidesTh Economopoulos
Jun 13, 2006·Urology·Aimee M JohnsonJay E Reeder
Aug 12, 2005·Current Opinion in Urology·Karen Giselle CheePrimo N Lara
Sep 24, 2009·Molecular Nutrition & Food Research·Alicja MortensenGerhard Sontag
Oct 30, 2015·Journal of the Royal Society, Interface·H HatzikirouM Meyer-Hermann
Jul 21, 2020·Clinical Pharmacology and Therapeutics·Vijayalakshmi ChelliahAndrzej M Kierzek
Apr 14, 2007·Molecular Cancer Therapeutics·Dorit NahariFiemu E Nwariaku

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis